Sector News

Obama looks to tackle pharma on prices and taxes

February 3, 2015
Life sciences
Healthcare has featured predominantly in President Obama’s $4 trillion budget submitted to the US Congress and observers have focused upon plans to let the government negotiate the price of drugs, his precision medicines initiative and a proposal to tax the foreign earnings of firms such as Pfizer and Merck & Co.
 
The president has proposed that the Department of Health and Human Services request proposes a budget authority of about $1.09 trillion for fiscal 2016, up from $1.04 trillion in fiscal 2015. Of that, $83.8 billion is discretionary funding, an increase of $4.8 billion from fiscal 2015.
 
One key proposal is that the HHS would be granted the power to negotiate with drugmakers over the price of specialty therapies under the US government’s Medicare Part D programme, which offers private coverage for senior citizens and the disabled. HHS Secretary Sylvia  Burwell said the move will help with the sky-high cost of some treatments.
 
Industry against price negotiation
 
However, commentators across the pond believe the proposal is unlikely to come to fruition, predicting opposition from Congress and industry. The Pharmaceutical Research and Manufacturers of America’s president John Castellani said that “while we support collaborative public and private efforts to advance biomedical research, the president’s budget includes harmful and misguided proposals that could undermine seniors’ access to care in the successful Medicare Parts D and B programmes and would hinder the development of new, life-saving medicines for patients.
 
Pres Obama also proposed a $215 million investment for his Precision Medicine Initiative, including $130 million for “a voluntary national research cohort of a million or more volunteers to propel our understanding of health and disease and set the foundation for a new way of doing research through engaged participants and open, responsible data sharing”. Some $70 million would go to the National Cancer Institute to scale up efforts to identify genomic drivers.
 
Other highlights of the budget include a proposal targeting US companies’ offshore profits with a one-time 14% tax to build a “21st century infrastructure,” to be used to repair roads, bridges and so on. Pres Obama also proposed setting up a separate agency to regulate food products, including possibly dietary supplements, which are currently covered by the US Food and Drug Administration. Meantime, the latter’s budget request is $4.9 billion, up 9% from 2015.
 
By Kevin Grogan
 
Source: Pharma Times

Related News

September 22, 2020

GSK’s Zejula and AZ’s Lynparza leap toward broader EU approval

Life sciences

GlaxoSmithKline’s Zejula and AstraZeneca’s Lynparza have both moved towards EU approval in new indications after receiving positive opinions from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human […]

September 22, 2020

Roche acquires Irish biotech firm Inflazome

Life sciences

Swiss pharma company Roche is set to acquire Irish biotech firm Inflazome for an upfront payment of $449m (€380m). In addition to the upfront payment, Inflazome is also eligible to […]

September 18, 2020

Eli Lilly, Amgen join forces to scale production of COVID-19 antibody cocktails

Life sciences

Months of fervid research have whittled away most potential options to treat patients with COVID-19, a group of antibody cocktails still hold promise. Eli Lilly believes so strongly in its contender that it’s […]